Big Pharma firms want a Republican in the White House judging by contributions received by the two US parties during the current campaign.
Outsourcing spend increases with Phase II budgets leading the way, study
Drugmakers are outsourcing a greater proportion of Phase II trial budgets and patient recruitment is still the most costly aspect of conducting such studies according to new research.
Sartorius Stedim Biotech sees single-use gains in H1; North American revs dip
Sartorius Stedim Biotech (SSB) has revised its full year guidance after its range of single-use products drove revenue gains in the first half of 2011.
ShangPharma revs up in Q4, but margins narrow
ShangPharma said it saw revenue climb on higher customer spending in the fourth quarter, but that margins slid due to currency effects and higher share-based compensation.
Wuxi finishes 2010 on a high, predicts growth in 2011
Wuxi PharmaTech finished the fourth quarter and the full year 2010 on a high driven by growth across all business units and the payoff from former suitor Charles River Laboratories (CRL).
Torrent investing in capacity to support international expansion
Torrent Pharma has begun construction of $75m API and formulation facilities in India to support its international expansion programme.
Bill strengthening FDA drug safety power enters congress
A bill to strengthen drug safety requirements and FDA powers has been introduced into the US congress.
Covance op income down as Phase III delays hit margins
Covance has recorded a 29 per cent drop in operating income, despite revenue growth, as cost reduction actions and Phase III delays hit margins.
Global expansion desirable but problematic; UPS survey
Nearly half of healthcare supply chain executives are planning to expand into emerging markets in the next 18 months, according to a UPS survey, but are concerned about the process.
Patheon op profit up 12%
Patheon has posted a 12 per cent growth in operating profit in the second quarter and said there is “strong evidence” the business environment is improving.
Sigma’s Q1 helped by HPAPI sales
Demand for HPAPIs helped US life science and technology supplier Sigma-Aldrich to a positive set of first quarter financials.
Kendle earnings hit by computer error
Kendle International posted a 22 per cent drop in net income to $5m, after a computer error led to problems with a clinical trial carried out for one of its customers.
Gerresheimer predicts drop in 2009 profits
Gerresheimer posted positive results for 2008, with operating income growing by over 13 per cent, but has acknowledged it will not be able to maintain this momentum in 2009.
All change at the top for pharma’s top 10
Pfizer is likely to lose its crown as the world’s largest pharmaceutical company and by 2012 will be usurped by GlaxoSmithKline, according to a report from Urch Publishing.
Gerresheimer’s Q3 buoyed up by drug sector focus
Gerresheimer’s decision to concentrate on the pharmaceutical and life science sectors and sell-off non-core divisions appears to be paying dividends judging by a 14 per cent jump in third quarter operating profit.
Agilent’s life science sales grow as profits drop
Agilent recorded strong third quarter revenue growth for its Bio-Analytical segment, which was tempered by the stagnation of income from its Electronic Measurement division.
Invitrogen and ABI post strong results
Invitrogen’s plans to buy Applied Biosystems (ABI) are on track with US antitrust regulators approving the deal and both firms achieving strong revenue growth.
Affymetrix slumps as pharma sales fall
Affymetrix slumped to an operating loss in the second quarter of 2008, reporting flat revenues and blaming a 30 per cent reduction in sales to the pharmaceutical sector.
Lab suppliers post solid Q2 growth despite the credit crisis
With fears of a global recession riding on the back of the credit crisis, many laboratory suppliers have managed to weather the storm and still achieve double digit sales growth in the second quarter of 2008.
Oncology drugs dominating the clinic
Oncology drugs are dominating the clinic, with studies on new
anti-cancer compounds representing the largest percentage of new
clinical trials initiated in 2007.
Pharma must adapt to emerging markets
Pharmaceutical companies are having to radically change their
practices when it comes to tackling emerging markets such as China,
India, Russia and Brazil, according to IMS.
Kendle reports record sales in Q1
Kendle has continued to perform well in its first quarter of 2008,
reporting record sales and new business gains, although its profit
was clouded by expenses.
Japan needs innovation to maintain pharma foothold
Although Japan's pharma market sits in firm second position on the
global stage, the country's foothold is slipping as other more
innovative countries grasp for a greater presence.
Long-term worries as Applied Bio posts flat Q3
Applied Biosystems (ABI) reported slight revenue rises in its third
quarter performance, but long term, the lab firm acknowledged its
instrument arm had been negatively affected by a weakened
Parexel, Covance report financial gains
Parexel and Covance have both reported strong financial gains in
their quarterly results, as the clinical services industry remains
Quintiles satisfies, study concludes
Quintiles Transnational has heralded the results of an
independently conducted study of clinical investigator sites across
Europe that saw the firm rate the highest overall in terms of
Emerging markets shine as mature markets stagnate
A new IMS Health report has confirmed that during 2007 it was the
emerging markets' time to shine in terms of prescription drug
Plastics division driving Gerresheimer in Q1
German packaging giant Gerresheimer reported a positive set of
first quarter results for 2008, largely due to the success of its
plastics division in the expanding medical plastics market.
Teva sprints ahead of the API field
With active pharmaceutical ingredient sales of $1,460m (€960.8m) in
2007 and a portfolio of more than 250 compounds, Teva
Pharmaceutical Industries is by a long stretch the dominant
supplier in the global API market.
India's largest CRAMS firm gathers momentum
Jubilant Organosys, India's largest custom research and
manufacturing services (CRAMS) provider, has scored new contracts
to the tune of $92m for the year thus far as its business continues
to gather momentum.
BASF sees hefty chemicals growth in 2007
Earnings growth from its pharma solutions business helped push
BASF's operating income (EBITDA) from fine chemicals up by 56.5 per
cent to €288m in 2007.
Qiagen lifted by acquisitions in '07
Qiagen announced strong Q4 results and good overall growth for
2007, despite going through significant integration and acquisition
efforts. The firm also gave guidance for a 40 per cent growth
rate in 2008.
Beckman Coulter sees earnings drop in Q4
Beckman Coulter saw its fourth quarter earnings held back by
the cost of acquiring NexGen Diagnostics, but the
underlying business was strong with a near-11 per cent hike in
Covance reports financial gains
Covance reported financial gains for its fourth quarter of 2007,
along with a 20.6 per cent growth in backlog to $2.7bn.
Parexel posts impressive Q2 profits
Parexel has reported positive financial results for the second
quarter of 2008.
Singapore's biomedical manufacturing down a third in December
Another sharp decline in biomedical production saw overall
manufacturing output in Singapore fall for the second month running
in December, prompting fears that the heavily trade-reliant economy
could buckle under a looming US recession.
Singapore's pharma output continues to slow
Singapore's biomedical manufacturing output was down again over
October, stunting growth for the region's entire manufacturing
New research offers CRO market snapshot
New research from Frost & Sullivan provides a snapshot of
biopharma spending trends on contract research organisations
(CROs), along with forecasts for industry growth.
Russia's clinical biz showing signs of recovery after biologics ban
Russia's clinical trials industry appears to be making a gradual
recovery from a setback earlier this year when the government
imposed an unexpected ban on biologic exports.
PharmaNet makes a Q3 comeback
PharmaNet has made a strong comeback during its third quarter after
previously slipping into the red and recorded its highest revenue
to date - $99.8m (€70.0m).
Icon improves its position, Kendle slips again
Icon has improved its financial position significantly during its
third quarter, while its smaller US rival Kendle saw its profit
slip again, weighed down by charges from a 2006 acquisition.
Parexel profits perky in Q1
Parexel has seen its profits remain perky during its first
financial quarter of 2008.
Covance posts healthy 3Q growth
Covance is feeling positive after reporting healthy growth in both
business units for the third quarter, with its early phase segment
continuing to have the edge over its late stage unit.
Applied Biosystems and Celera return first quarter profits
Applied Biosystems (ABI) saw 5 per cent revenue growth during its
first quarter of fiscal 2008 as sister company Celera posted
revenue growth of 57 per cent.
Singapore's output down
Figures released today reveal a slow-down in Singapore's
pharmaceutical manufacturing output compared to this time last
Sigma-Aldrich set to break $2bn yearly sales barrier
Sigma-Aldrich continued its strong year with both revenues and
pre-tax profits showing strong double-digit growth in the third
quarter predicting it will break the $2bn (€1.4bn) revenue mark
Veeco's revenues slide as restructuring hits home
Scanning probe microscope maker Veeco has seen its third quarter
revenues drop 13 per cent to $97.7m (€68.7m) and plans to make 100
staff redundant as part of a restructuring drive.
Demand for laboratory supplies continues unabated
As second quarter financial results continue to be released
laboratory suppliers Sigma-Aldrich and Invitrogen have both posted
13 per cent revenue growth.
Charles River performs well in Q2
Charles River Laboratories posted healthy financial results for its
second quarter, with both business units performing well.
Lab equipment manufacturers see record growth
With second quarter financial results being released thick and
fast, laboratory instrument manufacturers Bruker Biosciences and
Illumina have both seen very strong revenue growth.